Three-year follow-up of cerebrospinal fluid tau, β-amyloid 42 and 40 concentrations in Alzheimer's disease

Neuroscience Letters

Volumn 280, Issue 2, 2000, Pages 119-122

  Tapiola, Tero ^a   Pirttilä, Tuula ^a   Mikkonen, Mia ^a   Mehta, Pankaj D ^b   Alafuzoff, Irina ^a   Koivisto, Keijo ^a   Soininen, Hilkka ^a,c  

^a KUOPIO UNIVERSITY HOSPITAL   (Finland)

^b NEW YORK STATE INSTITUTE FOR BASIC RESEARCH IN DEVELOPMENTAL DISABILITIES   (United States)

^c UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

amyloid; Alzheimer's disease; Cerebrospinal fluid; Dementia; Tau

Indexed keywords

AMYLOID BETA PROTEIN; TAU PROTEIN;

AGED; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FOLLOW UP; HUMAN; PATIENT MONITORING; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN EXPRESSION;

AGED; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; BIOLOGICAL MARKERS; DISEASE PROGRESSION; FOLLOW-UP STUDIES; HUMANS; PEPTIDE FRAGMENTS; TAU PROTEINS; TIME FACTORS;

EID: 0033953722     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3940(00)00767-9     Document Type: Article

References (23)

1. (1-42) in Alzheimer's disease. Differences between early- and late-onset Alzheimer disease and stability during the course of disease. Arch. Neurol., 56 (1999) 673-680.
2. Andreasen, N., Vanmechelen, E., Van de Voorde, A., Davidsson, P., Hesse, C., Tarvonen, S., Räihä, I., Sourander, L., Winblad, B. and Blennow, K., Cerebrospinal fluid tau protein as a biochemical marker for Alzheimer's disease: a community based follow up study. J. Neurol. Neurosurg. Psychiatry, 64 (1998) 298-305.
3. Arai, H., Terajima, M., Miura, M., Higuchi, S., Muramatsu, T., Machida, N., Seiki, H., Takase, S., Clark, C.M., Lee, V.M-Y., Trojanowski, J.Q. and Sasaki, H., Tau in cerebrospinal fluid: a potential diagnostic marker in Alzheimer's disease. Ann. Neurol., 38 (1995) 649-652.
4. Blomberg, M., Jensen, M., Basun, H., Lannfelt, L. and Wahlund, L.O., Increasing cerebrospinal fluid tau levels in a subgroup of Alzheimer patients with apolipoprotein E allele ε4 during 14 months follow-up. Neurosci. Lett., 214 (1996) 163-166.
5. Clark, C., Sheppard, L., Fillenbaum, G., Galasko, D., Morris, J., Koss, E., Mohs, R. and Heyman, A., and the CERAD Investigators, Variability in annual mini-mental state examination score in patients with probable Alzheimer's disease: a clinical perspective of data from the Consortium to Establish a Registry for Alzheimer's disease. Arch. Neurol., 56(7) (1999) 857-862.
6. Galasko, D., Chang, L., Motter, R., Clark, C.M., Kaye, J., Knopman, D., Thomas, R., Kholodenko, D., Schenk, D., Lieberburg, I., Miller, B., Green, R., Basherad, R., Kertiles, L., Boss, M.A. and Seubert, P., High cerebrospinal fluid tau and low amyloid β42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. Arch. Neurol., 55 (1998) 937-945.
7. Galasko, D., Clark, C., Chang, L., Miller, B., Green, R.C., Motter, R. and Seubert, P., Assessment of CSF levels of tau protein in mildly demented patients with Alzheimer's disease. Neurology, 48 (1997) 632-635.
8. Heinonen, O., Lehtovirta, M., Soininen, H., Helisalmi, S., Mannermaa, A., Sorvari, H., Kosunen, O., Paljarvi, L., Ryynanen, M. and Riekkinen Sr., P.J., Alzheimer pathology of patients carrying apolipoprotein E epsilon 4 allele. Neurobiol. Aging, 16 (1995) 505-513.
9. Hock, C., Golombowski, S., Naser, W. and Muller-Spahn, F., Increased levels of τ protein in cerebrospinal fluid of patients with Alzheimer's disease-correlation with degree of cognitive impairment. Ann. Neurol., 37 (1995) 414-415.
10. Isoe, K., Urakami, K., Shimomura, T., Wakutani, Y., Ji, Y., Adachi, Y. and Takahashi, K., Tau proteins in cerebrospinal fluid from patients with Alzheimer's disease: a longitudinal study. Dementia, 7 (1996) 175-176.
11. Jensen, M., Schröder, J., Blomberg, M., Engwall, B., Pantel, J., Ida, N., Basun, H., Wahlund, L-O., Werle, E., Jauss, M., Beyreuther, K., Lannfelt, L. and Hartmann, T., Cerebrospinal fluid Aβ42 is increased early in sporadic Alzheimer's disease and declines with disease progression. Ann. Neurol., 45 (1999) 504-511.
12. Kanai, M., Matsubara, E., Isoe, K., Urakami, K., Nakashima, K., Arai, H., Sasaki, H., Abe, K., Iwatsubo, T., Kosaka, T., Watanabe, M., Tomidokoro, Y., Shizuka, M., Mizushima, K., Nakamura, T., Igeta, Y., Ikeda, Y., Amari, M., Kawarabayashi, T., Ishiguro, K., Harigaya, Y., Wakabayashi, K., Okamoto, K., Hirai, S. and Shoji, M., Longitudinal study of cerebrospinal fluid levels of tau, Abeta; 1-40, and Aβ 18-42(43) in Alzheimer's disease: a study in Japan. Ann. Neurol., 44 (1999) 17-26.
13. Kanai, M., Shizuka, M., Urakami, K., Matsubara, E., Harigaya, Y., Okamoto, K. and Shoji, M., Apolipoprotein E4 accelerates dementia and increases cerebrospinal fluid tau levels in Alzheimer's disease. Neurosci. Lett., 267 (1999) 65-68.
14. Kunicki, S., Richardson, J., Mehta, P.D., Kim, K.S. and Zorychta, E., The effects of age, apolipoprotein E phenotype and gender on the concentration of amyloid-β (Aβ) 40, Aβ42, apolipoprotein E and transthyretin in human cerebrospinal fluid. Clin. Biochem., 31 (1998) 409-415.
15. McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D. and Stadlan, E.M., Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology, 34 (1984) 939-944.
16. Mehta, P.D., Dalton, A.J., Mehta, S.P., Kim, K.S., Sersen, E.A. and Wisniewski, H.M., Increased plasma amyloid β protein 1-42 levels in Down syndrome. Neurosci. Lett., 241 (1998) 13-16.
17. 42 in the cerebrospinal fluid of patients with Alzheimer's disease. Ann. Neurol., 38 (1995) 643-648.
18. Nitsch, R.M., Rebeck, G.W., Deng, M., Richardson, U.I., Tennis, M., Schenk, D.B., Vigo-Pelfrey, C., Lieberburg, I., Wurtman, R.J., Hyman, B.T. and Growdon, J.H., Cerebrospinal fluid levels of amyloid β-protein in Alzheimer's disease: inverse correlation with severity of dementia and effect of apolipoprotein E genotype. Ann. Neurol., 37 (1995) 512-518.
19. Samuels, S.C., Silverman, J.M., Marin, D.B., Peskind, E.R., Younkin, S.G., Greenberg, D.A., Schnur, E., Santoro, J. and Davis, K.L., CSF beta-amyloid, cognition, and APOE genotype in Alzheimer's disease. Neurology, 52 (1999) 547-551.
20. Shoji, M., Matsubara, E., Kanai, M., Watanabe, M., Nakamura, T., Tomidokoro, Y., Shizuka, M., Wakabayashi, K., Igeta, Y., Ikeda, Y., Mizushima, K., Amari, M., Ishiguro, K., Kawarabayashi, T., Harigaya, Y., Okamoto, K. and Hirai, S., Combination assay of CSF tau. Aβ 1-40 and Aβ 1-42(43) as a biochemical marker of Alzheimer's disease. J. Neurol. Sci., 158 (1998) 134-140.
21. Tapiola, T., Lehtovirta, M., Ramberg, J., Helisalmi, S., Linnaranta, K., Riekkinen Sr., P. and Soininen, H., CSF tau is related to apolipoprotein E genotype in early Alzheimer's disease. Neurology, 50 (1998) 169-174.
22. Tato, R.E., Frank, A. and Hernanz, A., Tau protein concentrations in cerebrospinal fluid of patients with dementia of the Alzheimer type. J. Neurol. Neurosurg. Psychiatry, 59 (1995) 280-283.
23. Trojanowski, J.Q., Clark, C.M., Arai, H. and Lee, V.M-Y., Elevated levels of tau in cerebrospinal fluid: Implications for the antemortem diagnosis of Alzheimer's disease. Alz. Dis. Rev., 1 (1996) 77-83.